 Cortexyme Inc NASDAQ: CRTX shares are trading lower after the companys Phase 23 GAIN trial did not meet its co-primary endpoints. Cortexyme says they will present the additional top-line results from the GAIN Trial at the upcoming 14th Clinical Trials on Alzheimers Disease CTAD 2021 conference on Thursday, November 11 at 11:35 a.m. 